Clinical research on psychiatric disorders and migraines has concentrated on NK1 receptor antagonists.132 SSRIs are currently employed to cure mental illnesses because they prevent the uptake of 5-HT, which increases levels of 5-HT inside synaptic cleft.133,134 A novel category of antidepressants with therapeutic potential may be produced by combining SR inhibition mostly with modification of 5HT activity through NK1 antagonist.135–137. The gene discussed is HTR5A; the disease is migraine disorder.